<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320008</url>
  </required_header>
  <id_info>
    <org_study_id>KA92071gm</org_study_id>
    <nct_id>NCT00320008</nct_id>
  </id_info>
  <brief_title>Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria</brief_title>
  <acronym>Steno-2</acronym>
  <official_title>Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Gæde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intensified multifactorial intervention
      comprising both behaviour modification and polypharmacy can reduce the risk for late diabetic
      complications compared to standard treatment in patients with type 2 diabetes and
      microalbuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall description of the Steno-2 Study is stated in four protocols approved by the
      regulatory authorities in Denmark. The protocol identification numbers are KA 92071gm (4
      years intervention ), KA-99035g (8 years intervention ), KA-99035-GS (13 years follow-up
      since intervention start) and H-KA-99035-GS (21 year follow-up since intervention start).

      The aim of the study was to determine whether intensified multifactorial intervention
      comprising both behaviour modification and polypharmacy can reduce the risk for late diabetic
      complications compared to standard treatment in patients with type 2 diabetes and
      microalbuminuria. The primary end point after four years of intervention was to progression
      to diabetic nephropathy with other microvascular complications as secondary end points. The
      primary end point after eight years of intervention was a composite CVD endpoint with
      microvascular complications as secondary end points.

      The interventional part of the study was ended in December 2001 after a total of eight years
      of intervention. From that time on, all patients were followed in a post-trial study. Also,
      during post-trial period all patients in both original treatment arms received similar
      treatment resembling the treatment given in the original intensive arm of the study. The aim
      of the post-trial follow-up was to investigate the effect of intensified multifactorial
      intervention on i) mortality and ii) years of life gained, respectively, with such an
      interventional approach.

      Endpoints in the two parts of the post-trial follow-up:

      Part one at 13 years since start of intervention:

      Primary endpoint: Total mortality. Secondary endpoints: Cardiovascular endpoints as defined
      previously; Microvascular disease.

      Part two at 21 years since start of intervention:

      Primary endpoint: Difference in median time to 50% mortality in each of the two original
      treatment groups Secondary endpoints: Cardiovascular endpoints as defined previously;
      Recurrent cardiovascular events; Microvascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 1992</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetic nephropathy</measure>
    <time_frame>Four years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined cardiovascular endpoint</measure>
    <time_frame>Eight years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total mortality</measure>
    <time_frame>13 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Years of life years gained</measure>
    <time_frame>21 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular disease mortality</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary interventions</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputations</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular surgery</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic retinopathy</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic nephropathy</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic neuropathy</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet</intervention_name>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stop smoking</intervention_name>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose lowering therapy</intervention_name>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blood pressure lowering therapy</intervention_name>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipid lowering therapy</intervention_name>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Microalbuminuria

        Exclusion Criteria:

          -  Stimulated serum C-peptide concentration less than 600 pmol/L

          -  Pancreatic insufficiency or diabetes secondary to pancreatitis

          -  Alcohol abuse

          -  Non-diabetic kidney disease

          -  Life-threatening disease with death probable within 4 years of study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gaede, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Slagelse Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999 Feb 20;353(9153):617-22.</citation>
    <PMID>10030326</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.</citation>
    <PMID>12556541</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7;358(6):580-91. doi: 10.1056/NEJMoa0706245.</citation>
    <PMID>18256393</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center</investigator_affiliation>
    <investigator_full_name>Peter Gæde</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

